DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Treatment of Myelodysplastic Syndromes Comparing Hydralazine/Ac. Valproic and Supportive Care in Patients Not Candidates, Refractory and/or Intolerant to Intensive Chemotherapy

Information source: Basque Health Service
Information obtained from ClinicalTrials.gov on February 07, 2013
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Myelodysplastic Syndrome

Intervention: BSC (Drug); HIDRA/VPA (Drug)

Phase: Phase 2

Status: Not yet recruiting

Sponsored by: Basque Health Service

Overall contact:
Breno Moreno de Gusmao, MD, Phone: +34-945 007000, Email: breno.morenodegusmao@osakidetza.net

Summary

Transfusional dependence has been associated closely and independently with low survival in patients with myelodysplastic syndrome (MDS), especially in patients at low risk according to IPSS. Treatment of patients with hydralazine + valproic acid as an alternative to treatment with 5-azacytidine has lower cost and possibly as effective with fewer side effects. The objective of this phase II study is to determine the effectiveness of combination therapy with hydralazine + Ac. Valproic compared with best supportive care. The investigators will select 42 patients per group, and after 14 weeks of treatment the investigators will study in both groups the hematological response (transfusion-dependent, hemoglobin, cytogenetics and morphology) and treatment safety (adverse reactions and vital signs) to 1 year after starting treatment. The concentration of hemoglobin, the number of transfusions, platelets, neutrophils and other continuous variables in both groups will be compared by Student t or Mann-Whitney, as appropriate. For comparison of cytogenetic and morphological response and other categorical variables between groups Chi square will be used. And within each group the investigators will compare each of these variables before and after treatment by t-test for paired data or Wilcoxon test.

Clinical Details

Official title: Phase II Clinical Trial for Treatment of Myelodysplastic Syndromes Comparing Hydralazine / Ac.Valproico and Supportive Care in Patients Not Candidates, Refractory and / or Intolerant to Intensive Chemotherapy

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: change in hemoglobin from baseline in patients who express an erythroid response.

Secondary outcome: Erythroid response according to the criteria of the international working group of SMDs at 24 weeks

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

1. Ability to understand and voluntarily sign the consent form.

2. Age ≥ 18 years at the time of signing the informed consent form.

3. Ability and willingness to meet the schedule of study visits and other protocol requirements.

4. Documented diagnosis of SMDs according to the criteria of disease risk IPSS intermediate-2, high risk or any risk with transfusion requirements.

5. Transfusion-dependent anemia erythrocytes defined as the absence of a period of 56 consecutive days without transfusion of red blood cells for at least 112 days prior (16 weeks).

6. Engage both women and men to use highly effective contraception.

7. Patients are not candidates for treatment with azacitidine or chemotherapy

Exclusion Criteria:

- Patients who have any of these exclusion criteria may not be included in the trial:

1. Pregnant or breastfeeding.

2. After hematopoietic stem cell transplantation.

3. Patients with vitamin B12 deficiency, Folic Acid and Iron

4. Any severe psychiatric illness or condition that prevents the patient sign the consent form for the patient or involves an unacceptable risk in case of participating in the study.

5. Hypersensitivity to hydralazine and / or AC. Valproic

Locations and Contacts

Breno Moreno de Gusmao, MD, Phone: +34-945 007000, Email: breno.morenodegusmao@osakidetza.net

Txagorritxu Hospital, Vitoria-Gasteiz, Alava 01009, Spain; Not yet recruiting
Breno Moreno de Gusmao, MD, Phone: +34 945 007000, Email: breno.morenodegusmao@osakidetza.net
Additional Information

Starting date: September 2011
Last updated: May 19, 2011

Page last updated: February 07, 2013

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014